<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Platelet function testing</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Platelet function testing</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Platelet function testing</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Harrison, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gillian Lowe, MA MB BChir, MRCP, FRCPath</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lawrence LK Leung, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 19, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Platelets play a key role in hemostasis. Platelet dysfunction can cause a bleeding phenotype that may require specialist evaluation and interventions, especially during bleeding challenges (surgery, pregnancy, and trauma). </p><p>This topic summarizes available platelet function tests and provides information about how to interpret the results of platelet function testing.</p><p>Separate topics discuss a general approach to evaluating unexplained bleeding and the evaluation and management of specific platelet function disorders:</p><p class="bulletIndent1"><span class="glyph">●</span>General evaluation</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Child – (See  <a class="medical medical_review" href="/d/html/5936.html" rel="external">"Approach to the child with bleeding symptoms"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Adult – (See  <a class="medical medical_review" href="/d/html/1367.html" rel="external">"Approach to the adult with a suspected bleeding disorder"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Platelet disorders – (See  <a class="medical medical_review" href="/d/html/6675.html" rel="external">"Inherited platelet function disorders (IPFDs)"</a>.)</p><p></p><p>Platelet function testing does not have an established role in individuals with arterial thrombosis or those receiving antiplatelet therapy. Response to antiplatelet therapy is generally evaluated clinically. (See  <a class="medical medical_review" href="/d/html/16946.html" rel="external">"Nonresponse and resistance to aspirin"</a> and  <a class="medical medical_review" href="/d/html/6684.html" rel="external">"Clopidogrel resistance and clopidogrel treatment failure"</a>.)</p><p class="headingAnchor" id="H3594880584"><span class="h1">OVERVIEW</span></p><p class="headingAnchor" id="H3722155177"><span class="h2">When to order platelet function testing</span><span class="headingEndMark"> — </span>Generally, platelet function testing is indicated for an individual with a bleeding phenotype who has an unrevealing initial evaluation for more common bleeding disorders or bleeding out of proportion to mild abnormalities detected on initial laboratory evaluation  (<a class="graphic graphic_algorithm graphicRef138359" href="/d/graphic/138359.html" rel="external">algorithm 1</a>). </p><p>Indications for platelet function testing include:</p><p class="bulletIndent1"><span class="glyph">●</span>Unexplained bleeding with negative initial evaluation.</p><p class="bulletIndent1"><span class="glyph">●</span>Positive family history of a platelet function disorder.</p><p class="bulletIndent1"><span class="glyph">●</span>Genetic test results that suggest a platelet function disorder.</p><p></p><p>The initial evaluation that typically precedes platelet function testing includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Thorough history of bleeding challenges, using a bleeding assessment tool (BAT), and family history of bleeding disorders.</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count (CBC) with platelet count and examination of the peripheral blood smear.</p><p class="bulletIndent1"><span class="glyph">●</span>Standard coagulation testing with prothrombin time (PT) and activated partial thromboplastin time (aPTT).</p><p class="bulletIndent1"><span class="glyph">●</span>Screening tests for von Willebrand disease (may be omitted in some cases).</p><p></p><p>Details of the initial evaluation are presented separately:</p><p class="bulletIndent1"><span class="glyph">●</span>General evaluation – (See  <a class="medical medical_review" href="/d/html/1367.html" rel="external">"Approach to the adult with a suspected bleeding disorder"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Platelet count – (See  <a class="medical medical_review" href="/d/html/4430.html" rel="external">"Automated complete blood count (CBC)", section on 'Platelet parameters'</a>.)</p><p></p><p>Platelet function testing generally is not indicated to evaluate abnormal platelet morphology unless the individual is also under investigation for a bleeding disorder. However, morphology review and manual platelet count assessment on a peripheral blood smear is often assessed as an initial screen for possible platelet disorders, and, when abnormal, can suggest a platelet function disorder. Morphology review is rarely sufficient as the confirmatory diagnostic test for platelet disorders, since more definitive tests are available. Several studies have demonstrated that assessment of platelet size on the blood smear is biased. (See  <a class="medical medical_review" href="/d/html/4435.html" rel="external">"Evaluation of the peripheral blood smear", section on 'Platelets'</a>.)</p><p>Platelet function testing is generally<strong> </strong>not appropriate as a means of monitoring antiplatelet drugs or of predicting bleeding in patients with thrombocytopenia. </p><p class="headingAnchor" id="H2848209247"><span class="h2">Who should order testing</span><span class="headingEndMark"> — </span>Platelet function testing is rarely available in the community. This testing is mostly available in academic medical centers and is typically ordered by a hemostasis and thrombosis expert who has access to this testing and can determine whether testing is appropriate, which testing should be done, and in what order. These experts would normally see the patients to clinically assess their bleeding phenotype prior to requesting testing.</p><p>However, in rare cases, the community physician may order platelet function testing, and/or they may receive the results of the testing and may be asked to help interpret the results for the patient and/or other consultants.</p><p class="headingAnchor" id="H1133442105"><span class="h2">Which test(s) to order</span><span class="headingEndMark"> — </span>Following initial testing of hemostasis that suggests a platelet function disorder, platelet aggregometry is the gold standard test, and, when available, this is the most useful test for a patient with a suspected platelet function disorder. (See <a class="local">'Platelet aggregometry'</a> below.)</p><p>If aggregometry is not available, other platelet function tests are sometimes available that can be obtained more rapidly and may be easier to access and easier to use but that do not always have as well validated performance characteristics. These tests may be helpful in some cases, but in other cases it may be necessary to perform aggregometry, either for diagnostic confirmation or if results of these other tests are discordant with the clinical picture. (See <a class="local">'Other testing if aggregometry is not available'</a> below.)</p><p>Genetic testing may be appropriate in many cases, especially if a heritable platelet disorder is under consideration. This generally occurs <strong>after</strong> specialist review and platelet function testing, although some individuals may be notified of pathogenic variant in a gene involved in platelet function when they have genetic testing for another reason. (See <a class="local">'Evolving role of genetic testing'</a> below.) </p><p>Measurement of bleeding time is not recommended. Sophisticated imaging such as electron microscopy may be helpful for selected cases or for research. (See <a class="local">'Tests not commonly used'</a> below.)</p><p class="headingAnchor" id="H2691553357"><span class="h2">Caveats with testing</span><span class="headingEndMark"> — </span>The following caveats may apply to test selection and interpretation:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medications</strong> – Some medications interfere with platelet function and will cause falsely abnormal results on platelet function testing. Prior to platelet function testing, a patient will be asked about their medication history, including any antiplatelet agents, nonsteroidal anti-inflammatory drugs (NSAIDs), and selective serotonin receptor inhibitors (SSRIs), all of which interfere with platelet function. If clinically safe, these medications should be omitted for at least a week prior to platelet function testing [<a href="#rid1">1</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thrombocytopenia</strong> – Clinicians should be aware that platelet function testing can become unreliable in individuals with thrombocytopenia. There is not a strict platelet count cutoff below which this occurs. We generally avoid most of the platelet function tests (especially aggregometry) in individuals with a platelet count &lt;80,000 microL. </p><p></p><p class="bulletIndent1">However, some platelet function disorders are associated with thrombocytopenia, and laboratory assessment may be appropriate. In these cases, a method of platelet function testing independent of platelet count can be used, such as a flow cytometry-based method. (See <a class="local">'Flow cytometry'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Coagulation abnormalities</strong> – The coagulation cascade that produces the fibrin mesh in a clot is carried out by soluble factors in the circulation. For tests that assay hemostasis globally, clotting abnormalities may interfere with interpretation. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sample handling</strong> – Platelet aggregation studies are usually performed on fresh blood samples, ideally obtained without a tourniquet [<a href="#rid1">1</a>]. If needed, a tourniquet can be used initially and then removed after venipuncture (during blood collection). The needle size should be a 21 gauge or larger. Hemolyzed, clotted, or incompletely filled tubes should be rejected. Excessive agitation of the sample should be avoided. The sample should be maintained at room temperature (not refrigerated) and transported to the specialty testing laboratory without delay. </p><p></p><p class="headingAnchor" id="H8"><span class="h1">PLATELET AGGREGOMETRY</span></p><p class="headingAnchor" id="H445119974"><span class="h2">Uses of aggregometry</span><span class="headingEndMark"> — </span>Platelet aggregometry is the gold standard test for diagnosing platelet function disorders. It is generally the preferred test when a platelet function disorder is suspected  (<a class="graphic graphic_algorithm graphicRef138359" href="/d/graphic/138359.html" rel="external">algorithm 1</a>). </p><p>Aggregometry measures platelet response (aggregation) to a panel of agonists:</p><p class="bulletIndent1"><span class="glyph">●</span>Collagen</p><p class="bulletIndent1"><span class="glyph">●</span>Adenosine diphosphate (ADP)</p><p class="bulletIndent1"><span class="glyph">●</span>Epinephrine</p><p class="bulletIndent1"><span class="glyph">●</span>Ristocetin</p><p class="bulletIndent1"><span class="glyph">●</span>Arachidonic acid</p><p></p><p>Collagen, thrombin, ADP, and epinephrine are physiologic platelet activators. (See  <a class="medical medical_review" href="/d/html/1371.html" rel="external">"Overview of hemostasis", section on 'Platelet activation'</a>.)</p><p>Ristocetin is an antibiotic that was withdrawn from the market because it causes platelets to agglutinate. It is used in several different tests, including aggregometry, ristocetin-induced platelet activation (RIPA), and ristocetin cofactor activity of von Willebrand factor (VWF:RCo). RIPA and VWF:RCo are used to diagnose von Willebrand disease. (See  <a class="medical medical_review" href="/d/html/1307.html" rel="external">"Clinical presentation and diagnosis of von Willebrand disease", section on 'Platelet-dependent VWF activity (VWF:RCo or VWF:GPIbM)'</a>.) </p><p>A second-line panel of agonists can sometimes be used to further investigate abnormalities:</p><p class="bulletIndent1"><span class="glyph">●</span>U46619 (a thromboxane receptor agonist)</p><p class="bulletIndent1"><span class="glyph">●</span>Gamma thrombin</p><p class="bulletIndent1"><span class="glyph">●</span>TRAP (thrombin receptor activating peptides) that stimulate PAR-1 (peptide sequence SFLRRN) or PAR-4 (peptide sequence AYPGKF)</p><p class="bulletIndent1"><span class="glyph">●</span>Collagen Related Peptide (CRP) and Convulxin (a rattlesnake toxin), which stimulate platelet GpVI</p><p class="bulletIndent1"><span class="glyph">●</span>Calcium ionophore A23187</p><p class="bulletIndent1"><span class="glyph">●</span>Phorbol 12-myristate-13-acetate</p><p></p><p>Aggregometry can be performed in 96 well plates using measurements within standard plate readers [<a href="#rid2">2</a>]. This approach allows for the assessment of multiple concentrations of agonists, since the volume of platelets required for each test is significantly lower than with aggregometry. Agonists can be lyophilized to improve standardization, and test results can be analyzed rapidly using automated spreadsheets. Fully automated aggregometry is also available [<a href="#rid3">3</a>].</p><p>Aggregometry can be measured on platelet rich plasma (PRP) or whole blood.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>PRP</strong> – Standard aggregometry is measured on PRP, which is obtained by centrifuging anticoagulated blood at enough force to remove red blood cells (RBCs) but not platelets (170 to 200 times gravity for 10 to 15 minutes). The PRP is stirred in a cuvette at 37°C, the agonist is added, and light transmission through the sample is measured. Platelet aggregation (first as microaggregates and later as macroaggregates) decreases the turbidity of the sample and increases light transmission. A range of agonists can be tested, each at a range of concentrations. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Whole blood</strong> – Aggregometry on whole blood can be measured using electrical impedance with the Chronolog or Multiplate analyzer [<a href="#rid4">4</a>]. The blood is stirred in a cuvette at 37°C, and platelets adhere to the electrode [<a href="#rid5">5</a>]. Addition of agonists causes aggregation of additional platelets onto the electrode, which changes the impedance. The multiplate analyzer was demonstrated to be of value in screening for severe heritable platelet disorders but has lower sensitivity for milder disorders [<a href="#rid4">4</a>]. The multiplate analyzer has also been used as a point-of-care test and for monitoring antiplatelet therapy with standardized commercial reagents.</p><p></p><p class="bulletIndent1">The VerifyNow test is a type of whole blood aggregometry that has been automated. (See <a class="local">'VerifyNow'</a> below.)</p><p></p><p>The interpretation of platelet aggregometry depends on the specific pattern of aggregation to different agonists [<a href="#rid1">1,6</a>]. The figure  (<a class="graphic graphic_figure graphicRef56188" href="/d/graphic/56188.html" rel="external">figure 1</a>) shows typical aggregometry tracings for platelets from patients with a storage pool defect, Bernard-Soulier syndrome (BSS), and Glanzmann thrombasthenia (GT). The table  (<a class="graphic graphic_table graphicRef69518" href="/d/graphic/69518.html" rel="external">table 1</a>) summarizes the typical findings with these disorders in response to different agonists.</p><p>The classic distinction between BSS and GT is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>In BSS (defect in platelet GPIb complex), there is no agglutination in response to ristocetin. Response to other agonists is normal.</p><p class="bulletIndent1"><span class="glyph">●</span>In GT (defect in platelet GPIIb-IIIa complex), there is no response to ADP, epinephrine, thrombin, or collagen. Agglutination occurs in response to ristocetin. </p><p></p><p>In some granule disorders, the second wave of aggregation may be absent with weaker platelet agonists.</p><p><a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">Aspirin</a> and nonsteroidal anti-inflammatory drugs (NSAIDs) cause inhibition of cyclooxygenase and a poor response to arachidonic acid stimulation. Drugs that inhibit GPIIb-IIIa (eg, abciximab) can produce a similar pattern as GT, but testing suggests that the aggregometry results underestimate the severity of the platelet function defect [<a href="#rid7">7</a>]. Although there was initial interest in and much research on using aggregometry to monitor or assess response to antiplatelet therapies, this indication is not recommended. (See  <a class="medical medical_review" href="/d/html/16946.html" rel="external">"Nonresponse and resistance to aspirin"</a> and  <a class="medical medical_review" href="/d/html/6684.html" rel="external">"Clopidogrel resistance and clopidogrel treatment failure"</a>.)</p><p class="headingAnchor" id="H1070458391"><span class="h2">Caveats with aggregometry</span><span class="headingEndMark"> — </span>Aggregometry may be inaccurate in individuals with moderate to severe thrombocytopenia (platelet count &lt;80,000/microL). The platelet count is higher in PRP than in blood (acceptable range, 100,000 to 600,000/microL). (See <a class="local">'Caveats with testing'</a> above.)</p><p>Aggregometry is labor intensive and requires careful quality control and a fair degree of technical expertise in its performance and interpretation. Although modern aggregometers with multichannel capability, computer control, and the ability to measure adenosine triphosphate (ATP) release via luminescence have improved the technology, the test is currently limited to specialized laboratories and is not well standardized [<a href="#rid8">8-10</a>]. </p><p>Aggregometry may not be sensitive to all dense granule storage pool and release defects. Although genetic testing may help to establish a diagnosis, total platelet adenine nucleotides and their release have long been measured as a more specific test for these abnormalities. Real time incorporation of ATP release into platelet aggregometry (lumi-aggregometry) enables assessment of nucleotide release simultaneously with aggregation. Alternatively, the ATP and ADP levels can be measured in platelet lysates by luminometry. (See  <a class="medical medical_review" href="/d/html/1371.html" rel="external">"Overview of hemostasis", section on 'Platelet secretion'</a> and  <a class="medical medical_review" href="/d/html/6675.html" rel="external">"Inherited platelet function disorders (IPFDs)", section on 'Specific disorders'</a>.)</p><p>A number of efforts have attempted to improve standardization, including a 2015 guideline from the International Society on Thrombosis and Haemostasis (ISTH) [<a href="#rid11">11</a>]. </p><p class="headingAnchor" id="H57611039"><span class="h1">VISCOELASTIC TESTING (TEG AND ROTEM)</span><span class="headingEndMark"> — </span>Viscoelastic testing is often used to confirm that hemostasis is preserved, or to guide transfusions in individuals with global hemostatic disfunction such as during major surgery or trauma. This testing can detect abnormalities of all the phases of clotting, but they cannot distinguish between thrombocytopenia and platelet function defects. </p><p>Viscoelastic testing (referred to as a global hemostasis assay) is often performed on whole blood at the patient bedside or in the operating room. The tests assay the entire hemostatic process, from platelet activation and the coagulation cascade to clot formation and lysis. Rather than measuring a single endpoint such as a clotting time, they create a tracing that illustrates the different phases of clotting over time; the different components of the tracing indicate different phases of the process (platelet function, clotting, and fibrinolysis).</p><p>There are two main viscoelastic tests:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thromboelastography (TEG)</strong> – TEG is the most commonly used viscoelastic test. In the TEG and the related rapid TEG (r-TEG) devices, physical properties of the clot are measured by use of a cylindrical cup that holds a whole blood sample at 37ºC and is oscillated to and fro with a rotation cycle of 10 seconds. As the clot forms, the torque of the rotating cup is transmitted to an immersed pin. The degree of pin rotation is converted to an electrical signal via a transducer and monitored via a chart recorder. The strength of the developing clot increases the magnitude of the output, whereas during clot lysis, the bonds between the cup and the pin are broken, and the signal decreases. The forces that are generated are used to measure the clotting time, kinetics of clot initiation, clot strength, and clot lysis over time  (<a class="graphic graphic_table graphicRef74954" href="/d/graphic/74954.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1">The portions of the TEG tracing that assess platelet function are the alpha angle and the maximal amplitude, as illustrated in the figure  (<a class="graphic graphic_figure graphicRef100078" href="/d/graphic/100078.html" rel="external">figure 2</a>). </p><p></p><p class="bulletIndent1">There are several devices available commercially to measure TEG. While the specifics of the devices vary, they all measure the same general parameters. TEG instruments may be insensitive to samples from patients who have taken <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> [<a href="#rid12">12-14</a>]. However, the TEG PlateletMapping assay can overcome the limitations of thrombin-generated viscoelastic testing to reliably and accurately measure the ability of platelets to participate in clot formation and therefore measure the effects of antiplatelet drugs [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rotational thromboelastography (ROTEM)</strong> – The ROTEM device is an adaptation of the TEG in which the cup remains stationary and the pin rotates directly in the sample. Results obtained are essentially identical to the TEG.</p><p></p><p>The usefulness of these tests in general hematology practice remains uncertain. Indications for and uses of this testing are discussed in a 2018 Guideline from the British Society of Haematology [<a href="#rid16">16</a>]; more detailed information about these indications is presented separately:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgery</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>General</strong> – (See  <a class="medical medical_review" href="/d/html/112610.html" rel="external">"Intraoperative transfusion and administration of clotting factors", section on 'Use of a transfusion algorithm or protocol'</a> and  <a class="medical medical_review" href="/d/html/112610.html" rel="external">"Intraoperative transfusion and administration of clotting factors", section on 'Point-of-care tests'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cardiac</strong> – (See  <a class="medical medical_review" href="/d/html/126472.html" rel="external">"Anesthetic management for enhanced recovery after cardiac surgery (ERACS)", section on 'Hemostasis and blood management'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Liver transplant</strong> – (See  <a class="medical medical_review" href="/d/html/94585.html" rel="external">"Liver transplantation: Anesthetic management", section on 'Management of coagulopathy'</a> and  <a class="medical medical_review" href="/d/html/91242.html" rel="external">"Anesthesia for the patient with liver disease", section on 'Coagulation management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Trauma</strong> – (See  <a class="medical medical_review" href="/d/html/15147.html" rel="external">"Etiology and diagnosis of coagulopathy in trauma patients", section on 'Viscoelastic hemostatic assays'</a> and  <a class="medical medical_review" href="/d/html/15147.html" rel="external">"Etiology and diagnosis of coagulopathy in trauma patients"</a> and  <a class="medical medical_review" href="/d/html/117817.html" rel="external">"Ongoing assessment, monitoring, and resuscitation of the severely injured patient", section on 'VHA-based dosing'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postpartum hemorrhage</strong> – (See  <a class="medical medical_review" href="/d/html/6714.html" rel="external">"Postpartum hemorrhage: Medical and minimally invasive management", section on 'Viscoelastic testing'</a>.)</p><p></p><p class="headingAnchor" id="H1586722853"><span class="h1">OTHER TESTING IF AGGREGOMETRY IS NOT AVAILABLE</span><span class="headingEndMark"> — </span>Various other platelet function tests may be more readily available than aggregometry and may sometimes be obtained  (<a class="graphic graphic_table graphicRef138645" href="/d/graphic/138645.html" rel="external">table 3</a>). The best validated is the platelet function analyzer (PFA)-100 [<a href="#rid17">17</a>]. However, these tests are less useful than aggregometry. It is important that clinicians understand the limitations of this testing.</p><p class="headingAnchor" id="H3210055876"><span class="h2">PFA-100</span><span class="headingEndMark"> — </span>The PFA-100 or PFA-200 is a relatively automated test performed on whole blood that simulates in vivo platelet function. The test monitors a drop in flow rate as platelets form a hemostatic plug within a small aperture (150 microns) in a membrane coated with platelet agonists (collagen, epinephrine, or ADP) [<a href="#rid18">18-20</a>]. The result is a parameter called the closure time (CT); normal ranges are presented separately. (See  <a class="medical medical_society_guidelines" href="/d/html/115286.html" rel="external">"Laboratory test reference ranges in adults", section on 'Platelet function analysis (PFA-100)'</a>.)</p><p>The PFA-100 was originally validated using plasma from patients with von Willebrand disease (VWD), but it is not used to diagnose VWD because other testing is available with better performance characteristics that allows determination of the VWD subtype. (See  <a class="medical medical_review" href="/d/html/1307.html" rel="external">"Clinical presentation and diagnosis of von Willebrand disease"</a>.)</p><p>The main use of the PFA-100 is as a general screening test for platelet function when a specific diagnosis is not under consideration. In an individual with a positive bleeding history who does not have access to platelet aggregometry, the PFA-100 can be used, and, if abnormal, aggregometry can be used to confirm the diagnosis of a platelet function disorder and determine the likely diagnosis (Glanzmann thrombasthenia versus Bernard-Soulier syndrome versus another disorder). (See <a class="local">'Uses of aggregometry'</a> above.) </p><p>Advantages of the PFA-100 are its speed, ease of use, and lack of requirement for special training. The test only requires 0.8 mL of citrated whole blood for each cartridge, making it attractive for pediatric samples. Normal test results can exclude severe platelet defects but not milder disorders. </p><p>The PFA is affected by a number of variables including thrombocytopenia, anemia, and low von Willebrand factor (VWF) levels [<a href="#rid1">1</a>]. Other disadvantages include lack of specificity for a specific platelet function disorder and lack of sensitivity for and specificity for several disorders including primary secretion defects and storage pool disease. </p><p class="headingAnchor" id="H12"><span class="h2">VerifyNow</span><span class="headingEndMark"> — </span>The VerifyNow test is a modified aggregometry test that uses fibrinogen-coated beads that will agglutinate in whole blood in response to various platelet activators [<a href="#rid21">21</a>]. (See <a class="local">'Platelet aggregometry'</a> above.)</p><p>This test was marketed as a means of monitoring <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> therapy, P2Y<sub>12</sub> inhibitors such as <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a>, or GPIIb-IIIa inhibitors such as abciximab. </p><p class="headingAnchor" id="H29"><span class="h2">Flow cytometry</span><span class="headingEndMark"> — </span>Whole blood flow cytometry is a very powerful laboratory technique for assessing platelet activation and function [<a href="#rid22">22,23</a>]. </p><p>Flow cytometry can be performed on whole blood to assay platelet activation markers. It is one of the few techniques that is not adversely affected by thrombocytopenia. The following types of assays can be done:</p><p class="bulletIndent1"><span class="glyph">●</span>Assay for activation markers after exposure to platelet agonists. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Assay platelet surface glycoprotein deficiencies seen in heritable platelet disorders (GPIIb-IIIa in Glanzmann thrombasthenia; GPIb complex in Bernard-Soulier syndrome) [<a href="#rid24">24-26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Assay for dense granule deficiency and storage pool disease using a granule binding dye, mepacrine, in conjunction with platelet activation [<a href="#rid27">27,28</a>]. </p><p></p><p class="headingAnchor" id="H1849519776"><span class="h1">EVOLVING ROLE OF GENETIC TESTING</span><span class="headingEndMark"> — </span>The role of genetic testing in platelet function disorders is evolving. Greater accessibility of genetic testing, including multigene panels, may result in genetic testing being done before (or concurrently with) platelet function testing. Information about specific genetic variants and the platelet function disorders they cause is presented separately. (See  <a class="medical medical_review" href="/d/html/6675.html" rel="external">"Inherited platelet function disorders (IPFDs)", section on 'Specific disorders'</a>.)</p><p class="headingAnchor" id="H4173503947"><span class="h1">TESTS NOT COMMONLY USED</span><span class="headingEndMark"> — </span>For the majority of the 20<sup>th</sup> century, the only means of assessing platelet function were a small number of fairly unreliable tests (manual platelet count, inspection of the peripheral blood smear, bleeding time).</p><p>The following tests are not routinely used in the evaluation of platelet function disorders, although they may have a limited role in selected circumstances.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bleeding time</strong> – The bleeding time is rarely used and is mostly of historical interest. The test was invented in 1910 and was performed through the 1980s and perhaps beyond, but it has been supplanted by other testing [<a href="#rid29">29</a>]. It involves using a device to make a small cut on the patient's forearm and wiping away the blood without dislodging the clot until bleeding ceases. The test requires specialized training and is highly operator-dependent and time-consuming, and studies suggest it is not a good test to predict surgical bleeding [<a href="#rid30">30</a>]. It may leave a scar in some individuals. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Electron microscopy (EM)</strong> – EM can be extremely informative for certain disorders such as abnormalities of platelet granules. (See  <a class="medical medical_review" href="/d/html/6675.html" rel="external">"Inherited platelet function disorders (IPFDs)", section on 'Specific disorders'</a>.)</p><p></p><p class="bulletIndent1">However, it is labor-intensive and generally reserved for unusual cases or research studies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Less validated tests of hemostasis</strong> – A number of specialized tests have been developed that may be useful for research but have not been as well validated in clinical practice as aggregometry and other tests listed above. (See <a class="local">'Platelet aggregometry'</a> above and <a class="local">'Other testing if aggregometry is not available'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clot signature analyzer</strong> – The clot signature analyzer (CSA) is a test of global hemostasis that measures formation of a hemostatic plug in a tube with flowing blood. Platelets are activated by exposure to collagen in the tube or by punching a hole in the tube [<a href="#rid31">31,32</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Thrombotic status analyzer</strong> – The thrombotic status analyzer (TSA) measures platelet activation in whole blood in a capillary tube by assaying occlusion of the tube [<a href="#rid33">33</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cone and plate analyzer</strong> – The cone and plate(let) analyzer measures adhesion of platelets to extracellular matrix (ECM) under flow conditions using whole blood [<a href="#rid34">34-36</a>]. Platelet adhesion and aggregation on the surface of the plate are monitored by an image analyzer. Adhesion and aggregation require platelet GPIIb-IIIa, GPIb, and plasma von Willebrand factor (VWF). The test displays two parameters: surface coverage (SC) and average size (AS). The SC is a measure of the percentage of the plate covered by platelets, and the AS is the means size of surface bound objects</p><p></p><p class="bulletIndent2">The main advantages of this system are that it uses a small volume of blood (150 to 250 microL), yields results in 5 to 15 minutes, and exhibits a close resemblance to in vivo physiologic conditions.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Microfluidic devices</strong> – Researchers have developed a number of microfluidic devices that measure real time thrombus formation in whole blood. The main use of these devices is for research, but some approaches to investigate platelet function under flow within microfluidic devices appear promising in clinical settings [<a href="#rid37">37</a>]. One example is the Total Thrombus formation analysis system (T-TAS) [<a href="#rid38">38</a>]. This a flow-microchip chamber with thrombogenic surfaces that generates images of thrombi in real time that imitate vessel wall injury and produce quantitative data. T-TAS can be used for monitoring antithrombotic therapy and investigating patients with suspected platelet function defects. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>ICHOR POC Hematology Counter</strong> – When platelets within anticoagulated whole blood samples are stimulated by agonists (eg, ADP, epinephrine, ristocetin), they form aggregates, with a resulting reduction in the number of free platelets. A point-of-care (POC) assay that uses counting of the remaining platelets allows counting of platelets before and after agonist stimulation has been developed (ICHOR Point of Care Hematology Counter) [<a href="#rid39">39,40</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hemostatus device</strong> – The Hemostatus device is a POC device that measures platelet-mediated thrombin generation, a simple physiologic assay of platelet function. The activator is platelet activating factor and the assay is based on the kaolin-activated clotting time [<a href="#rid41">41,42</a>]. The test is insensitive to <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> and GPIb function, but it can detect abnormalities in GPIIb-IIIa. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hemodyne</strong> – The Hemodyne instrument assays global platelet function by measuring forces generated during clotting [<a href="#rid43">43</a>]. Platelet contractile force (PCF) is a test of global platelet function. It measures platelet activation by assaying clot retraction, which occurs following clot formation. Blood or platelet rich plasma is placed within a small cup between two parallel plates and treated with thrombin or other agonist. Retraction (size reduction) depends on initial activation with shape change and pseudopod formation, followed by adherence of pseudopods to a fibrin mesh (mediated by receptors such as GPIIb-IIIa). The retraction force is detected by a transducer. Two measurements are made [<a href="#rid44">44</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Platelet contractile force (PCF)</strong> – The force activated platelets exert on the fibrin network; this is abnormally low in thrombocytopenia, platelet function disorders, and with GPIIb-IIIa inhibitors [<a href="#rid45">45,46</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Elastic modulus (EM)</strong> – The rigidity of the clot; this is abnormally low in hypofibrinogenemia, clotting factor deficiencies, and with anticoagulants. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Soluble activation markers</strong> – In the research setting, platelet activation has been assayed using measurement of products released from activated platelets. In these methods, blood samples are usually collected into tubes containing inhibitors of platelet activation (<a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> and PGE<sub>1</sub>) and platelet-specific proteins are assayed. Examples of these proteins include platelet factor 4 (PF4) and thromboglobulin, which are released from alpha granules. The ratio of these two proteins often indicates if there has been a problem with artifactually induced activation.</p><p></p><p class="bulletIndent1">Other proteins assayed have included plasma soluble P-selectin, soluble CD40 ligand, glycoproteins V and VI, and thromboxane B<sub>2</sub> (a metabolite of thromboxane A<sub>2</sub>), or, in urine, the thromboxane metabolite 11-dehydrothromboxane B<sub>2</sub> [<a href="#rid47">47</a>]. P-selectin is an alpha granule marker that can also be assayed on the platelet surface by flow cytometry. (See <a class="local">'Flow cytometry'</a> above.)</p><p></p><p class="bulletIndent1">Uptake and release of radiolabeled serotonin from the dense granules was used in the past to assess storage and release defects. These assays have a number of disadvantages, including false elevation of levels due to sample handling, insensitivity, need for radioactive materials, and high cost.</p><p></p><p class="headingAnchor" id="H18121816"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – Platelet function testing is appropriate for unexplained bleeding with negative initial evaluation, or for bleeding out of proportion to mild abnormalities on laboratory testing  (<a class="graphic graphic_algorithm graphicRef138359" href="/d/graphic/138359.html" rel="external">algorithm 1</a>). It may also be indicated when there is a known platelet function disorder in a first-degree relative, or genetic test results suggestive of a platelet function disorder. Platelet function testing is generally<strong> </strong>not appropriate as a means of monitoring antiplatelet drugs or for predicting bleeding in patients with thrombocytopenia. Testing is mostly available in academic medical centers and generally ordered by hemostasis and thrombosis experts. (See <a class="local">'When to order platelet function testing'</a> above and <a class="local">'Who should order testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice of test</strong> – Platelet aggregometry is the gold standard test, and, when available, this is the most useful test for a patient with a suspected platelet function disorder. Testing may be inaccurate if the patient is taking an antiplatelet medication or has thrombocytopenia (platelet count &lt;80,000/microL). (See <a class="local">'Which test(s) to order'</a> above and <a class="local">'Caveats with testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aggregometry</strong> – Aggregometry measures platelet response (aggregation) to a panel of agonists (collagen, ADP, ristocetin)  (<a class="graphic graphic_figure graphicRef56188" href="/d/graphic/56188.html" rel="external">figure 1</a>). It can be performed on platelet rich plasma or whole blood. Interpretation depends on the pattern of response to specific agonists. The table  (<a class="graphic graphic_table graphicRef69518" href="/d/graphic/69518.html" rel="external">table 1</a>) summarizes the aggregometry findings in common disorders.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>TEG</strong> – Thromboelastography (TEG) and rotational thromboelastography (ROTEM) are point-of-care global hemostasis tests (also called viscoelastic tests) that assay platelet function, fibrin formation (coagulation factor function), and fibrinolysis (clot dissolution)  (<a class="graphic graphic_figure graphicRef100078" href="/d/graphic/100078.html" rel="external">figure 2</a>). The principle involves measuring the torque between a cup and pin as a clot forms and prevents rotation of one of the pieces (in TEG, the cup rotates; in ROTEM, the pin rotates). The main use of these tests is to guide transfusion during surgery, in trauma, and with postpartum hemorrhage. TEG and ROTEM cannot distinguish platelet dysfunction from thrombocytopenia. (See <a class="local">'Viscoelastic testing (TEG and ROTEM)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other functional tests</strong> – Several tests are more readily available than aggregometry  (<a class="graphic graphic_table graphicRef138645" href="/d/graphic/138645.html" rel="external">table 3</a>), but they have significant limitations. (See <a class="local">'Other testing if aggregometry is not available'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic testing</strong> – Genetic testing has an increasing role in diagnosing platelet function disorders. (See <a class="local">'Evolving role of genetic testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tests reserved for research or unusual cases</strong> – The bleeding time is of historical interest and is not indicated in investigation of bleeding disorders. Morphology review may be helpful but is prone to observer bias and is rarely sufficient to make a specific diagnosis. Electron microscopy is labor intensive and often reserved for unusual cases or research. (See <a class="local">'Tests not commonly used'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Gomez K, Anderson J, Baker P, et al. Clinical and laboratory diagnosis of heritable platelet disorders in adults and children: a British Society for Haematology Guideline. Br J Haematol 2021; 195:46.</a></li><li><a class="nounderline abstract_t">Chan MV, Armstrong PC, Warner TD. 96-well plate-based aggregometry. Platelets 2018; 29:650.</a></li><li><a class="nounderline abstract_t">Lawrie AS, Kobayashi K, Lane PJ, et al. The automation of routine light transmission platelet aggregation. Int J Lab Hematol 2014; 36:431.</a></li><li><a class="nounderline abstract_t">Al Ghaithi R, Drake S, Watson SP, et al. Comparison of multiple electrode aggregometry with lumi-aggregometry for the diagnosis of patients with mild bleeding disorders. J Thromb Haemost 2017; 15:2045.</a></li><li><a class="nounderline abstract_t">Mackie IJ, Jones R, Machin SJ. Platelet impedance aggregation in whole blood and its inhibition by antiplatelet drugs. J Clin Pathol 1984; 37:874.</a></li><li><a class="nounderline abstract_t">Hayward CP, Pai M, Liu Y, et al. Diagnostic utility of light transmission platelet aggregometry: results from a prospective study of individuals referred for bleeding disorder assessments. J Thromb Haemost 2009; 7:676.</a></li><li><a class="nounderline abstract_t">Mascelli MA, Worley S, Veriabo NJ, et al. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy. Circulation 1997; 96:3860.</a></li><li><a class="nounderline abstract_t">Cattaneo M, Hayward CP, Moffat KA, et al. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH. J Thromb Haemost 2009; 7:1029.</a></li><li><a class="nounderline abstract_t">Jennings I, Woods TA, Kitchen S, Walker ID. Platelet function testing: practice among UK National External Quality Assessment Scheme for Blood Coagulation participants, 2006. J Clin Pathol 2008; 61:950.</a></li><li><a class="nounderline abstract_t">Quiroga T, Goycoolea M, Matus V, et al. Diagnosis of mild platelet function disorders. Reliability and usefulness of light transmission platelet aggregation and serotonin secretion assays. Br J Haematol 2009; 147:729.</a></li><li><a class="nounderline abstract_t">Gresele P, Subcommittee on Platelet Physiology of the International Society on Thrombosis and Hemostasis. Diagnosis of inherited platelet function disorders: guidance from the SSC of the ISTH. J Thromb Haemost 2015; 13:314.</a></li><li><a class="nounderline abstract_t">Trentalange MJ, Walts LF. A comparison of thromboelastogram and template bleeding time in the evaluation of platelet function after aspirin ingestion. J Clin Anesth 1991; 3:377.</a></li><li><a class="nounderline abstract_t">Orlikowski CE, Payne AJ, Moodley J, Rocke DA. Thrombelastography after aspirin ingestion in pregnant and non-pregnant subjects. Br J Anaesth 1992; 69:159.</a></li><li><a class="nounderline abstract_t">Blais N, Pharand C, Lordkipanidzé M, et al. Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2). Thromb Haemost 2009; 102:404.</a></li><li><a class="nounderline abstract_t">Scharbert G, Auer A, Kozek-Langenecker S. Evaluation of the Platelet Mapping Assay on rotational thromboelastometry ROTEM. Platelets 2009; 20:125.</a></li><li><a class="nounderline abstract_t">Curry NS, Davenport R, Pavord S, et al. The use of viscoelastic haemostatic assays in the management of major bleeding: A British Society for Haematology Guideline. Br J Haematol 2018; 182:789.</a></li><li><a class="nounderline abstract_t">Lassila R. Platelet Function Tests in Bleeding Disorders. Semin Thromb Hemost 2016; 42:185.</a></li><li><a class="nounderline abstract_t">Kratzer MA, Born GV. Simulation of primary hemostasis in vitro. Hemostasis 1985; 5:357.</a></li><li><a class="nounderline abstract_t">Kundu SK, Heilmann EJ, Sio R, et al. Description of an in vitro platelet function analyzer--PFA-100. Semin Thromb Hemost 1995; 21 Suppl 2:106.</a></li><li><a class="nounderline abstract_t">Kundu SK, Heilmann EJ, Sio R, et al. Characterization of an In vitro Platelet Function Analyser, PFA-100TM. Clin Appl Thromb hemost 1996; 2:241.</a></li><li><a class="nounderline abstract_t">Kereiakes DJ, Mueller M, Howard W, et al. Efficacy of abciximab induced platelet blockade using a rapid point of care assay. J Thromb Thrombolysis 1999; 7:265.</a></li><li><a class="nounderline abstract_t">Michelson AD. Flow cytometry: a clinical test of platelet function. Blood 1996; 87:4925.</a></li><li><a class="nounderline abstract_t">Michelson AD, Furman MI. Laboratory markers of platelet activation and their clinical significance. Curr Opin Hematol 1999; 6:342.</a></li><li><a class="nounderline abstract_t">Shet AS, Aras O, Gupta K, et al. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood 2003; 102:2678.</a></li><li><a class="nounderline abstract_t">Weiss HJ. Scott syndrome: a disorder of platelet coagulant activity. Semin Hematol 1994; 31:312.</a></li><li><a class="nounderline abstract_t">Horstman LL, Ahn YS. Platelet microparticles: a wide-angle perspective. Crit Rev Oncol Hematol 1999; 30:111.</a></li><li><a class="nounderline abstract_t">Gordon N, Thom J, Cole C, Baker R. Rapid detection of hereditary and acquired platelet storage pool deficiency by flow cytometry. Br J Haematol 1995; 89:117.</a></li><li><a class="nounderline abstract_t">Wall JE, Buijs-Wilts M, Arnold JT, et al. A flow cytometric assay using mepacrine for study of uptake and release of platelet dense granule contents. Br J Haematol 1995; 89:380.</a></li><li><a class="nounderline abstract_t">Duke WW. The relation of blood platelets to hemorrhagic disease. JAMA 1910; 55:1185.</a></li><li><a class="nounderline abstract_t">Rodgers RP, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost 1990; 16:1.</a></li><li><a class="nounderline abstract_t">Li CK, Hoffmann TJ, Hsieh PY, et al. Xylum CSA: automated system for assessing hemostasis in simulated vascular flow. Clin Chem 1997; 43:1788.</a></li><li><a class="nounderline abstract_t">Conan K, Li N, Hoffmann TJ, et al. The Xylum Clot Signature Analyser: A dynamic flow sytstem that simulates vascular injury. Thromb Res 1998; 92:S677.</a></li><li><a class="nounderline abstract_t">Gorog DA, Kovacs IB. Thrombotic status analyser. Measurement of platelet-rich thrombus formation and lysis in native blood. Thromb Haemost 1995; 73:514.</a></li><li><a class="nounderline abstract_t">Varon D, Dardik R, Shenkman B, et al. A new method for quantitative analysis of whole blood platelet interaction with extracellular matrix under flow conditions. Thromb Res 1997; 85:283.</a></li><li><a class="nounderline abstract_t">Varon D, Lashevski I, Brenner B, et al. Cone and plate(let) analyzer: monitoring glycoprotein IIb/IIIa antagonists and von Willebrand disease replacement therapy by testing platelet deposition under flow conditions. Am Heart J 1998; 135:S187.</a></li><li><a class="nounderline abstract_t">Kenet G, Lubetsky A, Shenkman B, et al. Cone and platelet analyser (CPA): a new test for the prediction of bleeding among thrombocytopenic patients. Br J Haematol 1998; 101:255.</a></li><li><a class="nounderline abstract_t">de Witt SM, Swieringa F, Cavill R, et al. Identification of platelet function defects by multi-parameter assessment of thrombus formation. Nat Commun 2014; 5:4257.</a></li><li><a class="nounderline abstract_t">Al Ghaithi R, Mori J, Nagy Z, et al. Evaluation of the Total Thrombus-Formation System (T-TAS): application to human and mouse blood analysis. Platelets 2019; 30:893.</a></li><li><a class="nounderline abstract_t">Carville DG, Schleckser PA, Guyer KE, et al. Whole blood platelet function assay on the ICHOR point-of-care hematology analyzer. J Extra Corpor Technol 1998; 30:171.</a></li><li><a class="nounderline abstract_t">Campbell J, Ridgway H, Carville D. Plateletworks: a novel point of care platelet function screen. Mol Diagn Ther 2008; 12:253.</a></li><li><a class="nounderline abstract_t">Despotis GJ, Levine V, Filos KS, et al. Evaluation of a new point-of-care test that measures PAF-mediated acceleration of coagulation in cardiac surgical patients. Anesthesiology 1996; 85:1311.</a></li><li><a class="nounderline abstract_t">Despotis GJ, Levine V, Saleem R, et al. Use of point-of-care test in identification of patients who can benefit from desmopressin during cardiac surgery: a randomised controlled trial. Lancet 1999; 354:106.</a></li><li><a class="nounderline abstract_t">Carr ME Jr, Zekert SL. Measurement of platelet-mediated force development during plasma clot formation. Am J Med Sci 1991; 302:13.</a></li><li><a class="nounderline abstract_t">Carr ME Jr. Measurement of platelet force: the Hemodyne hemostasis analyzer. Clin Lab Manage Rev 1995; 9:312.</a></li><li><a class="nounderline abstract_t">Greilich PE, Carr ME Jr, Carr SL, Chang AS. Reductions in platelet force development by cardiopulmonary bypass are associated with hemorrhage. Anesth Analg 1995; 80:459.</a></li><li><a class="nounderline abstract_t">Carr ME Jr, Carr SL, Hantgan RR, Braaten J. Glycoprotein IIb/IIIa blockade inhibits platelet-mediated force development and reduces gel elastic modulus. Thromb Haemost 1995; 73:499.</a></li><li><a class="nounderline abstract_t">Fijnheer R, Frijns CJ, Korteweg J, et al. The origin of P-selectin as a circulating plasma protein. Thromb Haemost 1997; 77:1081.</a></li></ol></div><div id="topicVersionRevision">Topic 4433 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34435350" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical and laboratory diagnosis of heritable platelet disorders in adults and children: a British Society for Haematology Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29543546" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : 96-well plate-based aggregometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24237750" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The automation of routine light transmission platelet aggregation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28762630" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Comparison of multiple electrode aggregometry with lumi-aggregometry for the diagnosis of patients with mild bleeding disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6206096" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Platelet impedance aggregation in whole blood and its inhibition by antiplatelet drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19143930" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Diagnostic utility of light transmission platelet aggregometry: results from a prospective study of individuals referred for bleeding disorder assessments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9403608" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19422455" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18663056" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Platelet function testing: practice among UK National External Quality Assessment Scheme for Blood Coagulation participants, 2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19775303" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Diagnosis of mild platelet function disorders. Reliability and usefulness of light transmission platelet aggregation and serotonin secretion assays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25403439" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Diagnosis of inherited platelet function disorders: guidance from the SSC of the ISTH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1931061" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A comparison of thromboelastogram and template bleeding time in the evaluation of platelet function after aspirin ingestion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1389819" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Thrombelastography after aspirin ingestion in pregnant and non-pregnant subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19652893" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19235055" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Evaluation of the Platelet Mapping Assay on rotational thromboelastometry ROTEM.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30073664" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The use of viscoelastic haemostatic assays in the management of major bleeding: A British Society for Haematology Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26886396" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Platelet Function Tests in Bleeding Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Simulation of primary hemostasis in vitro</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7660150" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Description of an in vitro platelet function analyzer--PFA-100.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Characterization of an In vitro Platelet Function Analyser, PFA-100TM</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10375388" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Efficacy of abciximab induced platelet blockade using a rapid point of care assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8652804" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Flow cytometry: a clinical test of platelet function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10468151" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Laboratory markers of platelet activation and their clinical significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12805058" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7831576" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Scott syndrome: a disorder of platelet coagulant activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10439058" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Platelet microparticles: a wide-angle perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7833250" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Rapid detection of hereditary and acquired platelet storage pool deficiency by flow cytometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7873389" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A flow cytometric assay using mepacrine for study of uptake and release of platelet dense granule contents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The relation of blood platelets to hemorrhagic disease</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2406907" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A critical reappraisal of the bleeding time.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9299980" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Xylum CSA: automated system for assessing hemostasis in simulated vascular flow.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The Xylum Clot Signature Analyser: A dynamic flow sytstem that simulates vascular injury</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7667836" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Thrombotic status analyser. Measurement of platelet-rich thrombus formation and lysis in native blood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9062952" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A new method for quantitative analysis of whole blood platelet interaction with extracellular matrix under flow conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9588399" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cone and plate(let) analyzer: monitoring glycoprotein IIb/IIIa antagonists and von Willebrand disease replacement therapy by testing platelet deposition under flow conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9609519" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Cone and platelet analyser (CPA): a new test for the prediction of bleeding among thrombocytopenic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25027852" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Identification of platelet function defects by multi-parameter assessment of thrombus formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30365350" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Evaluation of the Total Thrombus-Formation System (T-TAS): application to human and mouse blood analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10537577" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Whole blood platelet function assay on the ICHOR point-of-care hematology analyzer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18652521" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Plateletworks: a novel point of care platelet function screen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8968178" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Evaluation of a new point-of-care test that measures PAF-mediated acceleration of coagulation in cardiac surgical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10408485" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Use of point-of-care test in identification of patients who can benefit from desmopressin during cardiac surgery: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2063881" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Measurement of platelet-mediated force development during plasma clot formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10144345" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Measurement of platelet force: the Hemodyne hemostasis analyzer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7864408" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Reductions in platelet force development by cardiopulmonary bypass are associated with hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7667835" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Glycoprotein IIb/IIIa blockade inhibits platelet-mediated force development and reduces gel elastic modulus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9241736" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The origin of P-selectin as a circulating plasma protein.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
